Quest Diagnostics (NYSE:DGX – Get Free Report) posted its earnings results on Tuesday. The medical research company reported $2.35 EPS for the quarter, topping the consensus estimate of $2.31 by $0.04, Briefing.com reports. The company had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.39 billion. Quest Diagnostics had a net margin of 8.99% and a return on equity of 15.49%. The company’s revenue for the quarter was up 2.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.30 earnings per share. Quest Diagnostics updated its FY 2024 guidance to 8.800-9.000 EPS and its FY24 guidance to $8.80-9.00 EPS.
Quest Diagnostics Price Performance
Shares of NYSE DGX traded up $0.34 during trading on Thursday, reaching $144.25. The company had a trading volume of 1,126,418 shares, compared to its average volume of 990,983. Quest Diagnostics has a 52 week low of $119.59 and a 52 week high of $150.59. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.89 and a current ratio of 0.97. The business’s 50 day moving average price is $141.06 and its 200-day moving average price is $134.39. The stock has a market cap of $16.02 billion, a PE ratio of 19.37, a PEG ratio of 3.00 and a beta of 0.89.
Quest Diagnostics Announces Dividend
The business also recently disclosed a quarterly dividend, which was paid on Monday, July 22nd. Shareholders of record on Monday, July 8th were issued a dividend of $0.75 per share. This represents a $3.00 dividend on an annualized basis and a yield of 2.08%. The ex-dividend date of this dividend was Monday, July 8th. Quest Diagnostics’s dividend payout ratio is currently 40.38%.
Wall Street Analysts Forecast Growth
Get Our Latest Stock Report on DGX
Insider Activity at Quest Diagnostics
In related news, SVP Karthik Kuppusamy sold 1,760 shares of Quest Diagnostics stock in a transaction dated Monday, April 29th. The stock was sold at an average price of $140.00, for a total value of $246,400.00. Following the completion of the sale, the senior vice president now directly owns 13,435 shares in the company, valued at $1,880,900. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.79% of the stock is currently owned by company insiders.
Quest Diagnostics Company Profile
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.
Recommended Stories
- Five stocks we like better than Quest Diagnostics
- How to invest in marijuana stocks in 7 stepsĀ
- Viking Therapeutics: Pharma Stock Soars on Positive Earnings
- 3 Monster Growth Stocks to Buy Now
- Top 3 Small Cap Stocks Emerging as Rotation Winners
- The 3 Best Retail Stocks to Shop for in August
- Bargain Alert: 3 Stocks Worth Watching While The Market Cools
Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.